TP53 and cancer: Subsequently, RanBP17 RNAi knockdown was performed on a panel of HNSCC cell lines (UM-SCC-4, UT-SCC-26A, UM-SCC-3 and UM-SCC-27) including a colon (HCT116), a lung (H460) and a breast (MDA-MB-231) cancer cell line, the latter three together with their respective CRISPR/Cas9 TP53 knockout counterparts (Fig. 1B).